These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25619468)

  • 61. HPV vaccination - a paradigm shift in public health.
    May J
    Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
    Pomfret TC; Gagnon JM; Gilchrist AT
    J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Research status of human papillomavirus vaccine for prevention and treatment of respiratory papillomatosis].
    Pan XF; Wang J; Xiao Y
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Feb; 33(2):189-192. PubMed ID: 30808153
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma.
    Shah KV
    J Infect Dis; 2014 May; 209(9):1307-9. PubMed ID: 24265442
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Gardasil: Introducing the new human papillomavirus vaccine.
    McLemore MR
    Clin J Oncol Nurs; 2006 Oct; 10(5):559-60. PubMed ID: 17063609
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis.
    Mauz PS; Schäfer FA; Iftner T; Gonser P
    BMC Infect Dis; 2018 Jul; 18(1):343. PubMed ID: 30041619
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
    Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
    Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.
    So RJ; Rayle C; Joo HH; Huang EY; Seiwert TY; Raabe EH; Best SR
    Laryngoscope; 2024 Jul; 134(7):3253-3259. PubMed ID: 38525973
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children.
    Rogers DJ; Ojha S; Maurer R; Hartnick CJ
    JAMA Otolaryngol Head Neck Surg; 2013 May; 139(5):496-501. PubMed ID: 23681032
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis.
    Kashima HK; Shah F; Lyles A; Glackin R; Muhammad N; Turner L; Van Zandt S; Whitt S; Shah K
    Laryngoscope; 1992 Jan; 102(1):9-13. PubMed ID: 1309932
    [TBL] [Abstract][Full Text] [Related]  

  • 72. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Epidemiology of recurrent respiratory papillomatosis.
    Larson DA; Derkay CS
    APMIS; 2010 Jun; 118(6-7):450-4. PubMed ID: 20553527
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Decreasing risk: impact of HPV vaccination on outcomes.
    Hymel PA
    Am J Manag Care; 2006 Dec; 12(17 Suppl):S473-83. PubMed ID: 17203991
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis.
    Major T; Sziklai I; Czeglédy J; Gáll T; Gergely L; Szarka K
    Anticancer Res; 2008; 28(4B):2169-74. PubMed ID: 18751391
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intralesional cidofovir as adjuvant for the successful management of aggressive respiratory papillomatosis in an infant.
    Durvasula VS; Richter GT
    Int J Pediatr Otorhinolaryngol; 2013 Nov; 77(11):1912-5. PubMed ID: 24063771
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A human papillomavirus vaccine.
    Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):65-6. PubMed ID: 16977280
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
    Block SL; Nolan T; Sattler C; Barr E; Giacoletti KE; Marchant CD; Castellsagué X; Rusche SA; Lukac S; Bryan JT; Cavanaugh PF; Reisinger KS;
    Pediatrics; 2006 Nov; 118(5):2135-45. PubMed ID: 17079588
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.
    Lacey CJ; Lowndes CM; Shah KV
    Vaccine; 2006 Aug; 24 Suppl 3():S3/35-41. PubMed ID: 16950016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.